Effectiveness of 225Ac-labeled anti-EGFR radio immunoconjugate in EGFR positive KRAS and BRAF mutant colorectal cancer models

被引：0
|
作者：
Tikum, Anjong [1 ]
Babeker, Hanan [2 ]
Ketchemen, Jessica Pougoue [2 ]
Fonge, Humphrey [2 ]
Njotu, Fabrice Ngoh [2 ]
Nambisan, Anand [2 ]
Doroudi, Alireza [2 ]
机构：
[1] Univ Saskatchewan Bookstore, Saskatoon, SK, Canada
[2] Univ Saskatchewan, Saskatoon, SK, Canada
来源：
JOURNAL OF NUCLEAR MEDICINE | 2023年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
P222
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Effectiveness of 225Ac-Labeled Anti-EGFR Radioimmunoconjugate in EGFR-Positive Kirsten Rat Sarcoma Viral Oncogene and BRAF Mutant Colorectal Cancer Models
    Tikum, Anjong Florence
    Ketchemen, Jessica P.
    Doroudi, Alireza
    Nambisan, Anand K.
    Babeker, Hanan
    Njotu, Fabrice Ngoh
    Fonge, Humphrey
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (03) : 402 - 408
  • [2] Therapeutic efficacy of 225Ac-labeled nimotuzumab in a mouse model of EGFR positive KRAS-mutant metastatic colorectal cancer (mCRC)
    Khan, Behlol
    Khan, Musharraf
    Causey, Patrick
    Perron, Randy
    Gendron, Denise
    Karkare, Sharayu
    Parada, Angel C.
    Geyer, Clarence R.
    Fonge, Humphrey
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [3] 225Ac-labeled anti-EGFR antibody drug radioconjugate elicits durable anti-tumor responses in mouse models of colorectal cancer
    Tikum, F.
    Henning, N.
    Doroudi, A.
    Ketchemen, J.
    Babeker, H.
    Njotu, F.
    Monzer, A.
    Nwangele, E.
    Uppalapati, M.
    Gray, B.
    Torlakovic, E.
    Fonge, H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S321 - S322
  • [4] Biomarkers of resistance to anti-EGFR in wild type KRAS/BRAF colorectal cancer cell lines
    Kumar, S. Sree
    Price, T.
    Hardingham, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S493 - S493
  • [5] The oligoclonal anti-EGFR antibody MM-151 synergizes with trametinib in KRAS wildtype and mutant colorectal cancer models resistant to conventional monoclonal anti-EGFR antibodies
    Landenranta, J.
    Gerami-Moayed, N.
    Burenkova, O.
    Masson, K.
    Raue, A.
    Wainszelbaum, M.
    MacBeath, G.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S131 - S131
  • [6] Response to BRAF inhibitors combined with anti-EGFR after previous anti-EGFR exposure for BRAF V600E mutant metastatic colorectal cancer patients
    Hafliger, E.
    Boccaccino, A.
    El-Khoury, R.
    Perret, A.
    Pietrantonio, F.
    Pilla, L.
    Lecomte, T.
    Scartozzi, M.
    Soularue, E.
    Salvatore, L.
    Bourgeois, V.
    Salati, M.
    Vaillant, J. N.
    Gallois, C.
    Lonardi, S.
    Cremolini, C.
    Taieb, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S554 - S554
  • [7] Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
    Gattenloehner, S.
    Etschmann, B.
    Kunzmann, V.
    Thalheimer, A.
    Hack, M.
    Kleber, G.
    Einsele, H.
    Germer, C.
    Mueller-Hermelink, H. -K.
    JOURNAL OF ONCOLOGY, 2009, 2009
  • [8] Simvastatin induces KRAS translocation in KRAS mutant colorectal cancer cells and may influence the susceptibility to anti-EGFR therapy
    Krens, L.
    Pullen, C. M. C.
    Baak-Pablo, R. F.
    Guchelaar, H. J.
    van der Straaten, R. J. H. M.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S495 - S495
  • [9] BENEFIT FROM ANTI-EGFR THERAPY IN KRAS, BRAF, NRAS, PI3KCA "ALL WILD TYPE", EGFR POSITIVE COLORECTAL CANCER PATIENTS.
    De Maglio, Giovanna
    Aprile, Giuseppe
    Foltran, Luisa
    Masiero, Elena
    Lutrino, Stefania
    Cardellino, Giovanni
    Fontanella, Caterina
    Fasola, Gianpiero
    Pizzolitto, Stefano
    ANNALS OF ONCOLOGY, 2011, 22 : v107 - v107
  • [10] PREDICTIVE MOLECULAR BIOMARKERS IN COLORECTAL CANCER: IS KRAS AND BRAF WILD TYPE STATUS REQUIRED FOR ANTI-EGFR THERAPY?
    Marchoudi, N.
    Joutei, H. Amrani Hassani
    Jouali, F.
    Fekkak, J.
    Rhaissi, H.
    ANTICANCER RESEARCH, 2014, 34 (10) : 6048 - 6048
12345